Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDE...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchesi, Francesco, Salmanton-García, Jon, Buquicchio, Caterina, Itri, Federico, Besson, Caroline, Dávila-Valls, Julio, Martín-Pérez, Sonia, Fianchi, Luana, Rahimli, Laman, Tarantini, Giuseppe, Grifoni, Federica Irene, Sciume, Mariarita, Labrador, Jorge, Cordoba, Raul, López-García, Alberto, Fracchiolla, Nicola S., Farina, Francesca, Ammatuna, Emanuele, Cingolani, Antonella, García-Bordallo, Daniel, Gräfe, Stefanie K., Bilgin, Yavuz M., Dargenio, Michelina, González-López, Tomás José, Guidetti, Anna, Lahmer, Tobias, Lavilla-Rubira, Esperanza, Méndez, Gustavo-Adolfo, Prezioso, Lucia, Schönlein, Martin, Van Doesum, Jaap, Wolf, Dominik, Hersby, Ditte Stampe, Magyari, Ferenc, Van Praet, Jens, Petzer, Verena, Tascini, Carlo, Falces-Romero, Iker, Glenthøj, Andreas, Cornely, Oliver A., Pagano, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066993/
https://www.ncbi.nlm.nih.gov/pubmed/37005697
http://dx.doi.org/10.1186/s13045-023-01423-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10066993/
https://www.ncbi.nlm.nih.gov/pubmed/37005697
http://dx.doi.org/10.1186/s13045-023-01423-7

Ejemplares similares